Aerie Pharma (AERI) Misses Q2 EPS by 3c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Wall St futures muted as oil gains curb risk appetite after S&P record close
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- Reddit to join S&P 500 index on Aug. 18, shares leap
Aerie Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Business Update
August 4, 2021 4:01 PM EDTSecond Quarter 2021 Net Revenues of $27.2 Million Increased 50.8% over Second Quarter 2020
Second Quarter 2021 Net Revenue Per Bottle of $89, up 14.7% over Second Quarter 2020
Phase 2b Topline Results for AR-15512 (COMET-1) Expected in the Third Quarter of 2021
Conference Call and Webcast Today, August 4th, at 5:00 p.m. ET
DURHAM, N.C.--(BUSINESS WIRE)-- Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with... More
